CliffBio
small molecule

MYTESI

CROFELEMER

Loss of exclusivityOctober 2031latest FDA-listed patent expiry
CompanyNapo Pharmaceuticals, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameMYTESI
Active ingredientCROFELEMER
Strength125MG
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2012
Marketing statusRX

Listed patents

PatentExpiresType
9585868October 2031use U-1319
8962680October 2031use U-1319

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.